Therapeutic effects of chloroquine in combination with quinine in uncomplicated falciparum malaria
- PMID: 8758141
- DOI: 10.1080/00034983.1996.11813052
Therapeutic effects of chloroquine in combination with quinine in uncomplicated falciparum malaria
Abstract
The efficacy and toxicity of oral quinine combined with oral chloroquine were studied in 50 Thai men with uncomplicated falciparum malaria. All were treated for 7 days with quinine sulphate (10 mg salt/kg every 8 h). Twenty-five of the patients, selected at random, were also given oral tetracycline (4 mg/kg four times daily) over the same period and the remainder were given chloroquine (25 mg base/kg over the first 3 days). There were no serious adverse effects. Overall fever-clearance times (FCT) and parasite-clearance times (PCT) in the chloroquine and tetracycline groups were not significantly different, with mean (S.D.) values of 51 (33) and 41 (27) h for FCT and 80 (25) and 83 (21) h for PCT, respectively. Most of the patients (18 in each group) were followed for > or = 2 months. Recrudescence rates (R1) were significantly higher in the chloroquine group than in the tetracycline group (39% v. 6%; P = 0.02), all recrudescences occurring within 4 weeks (18-25 days) of starting treatment. Subsequent parasitaemia with Plasmodium vivax, however, occurred less frequently in the chloroquine group (11%) than in the tetracycline group (33%) (P = 0.11) and took longer to develop in the chloroquine group [51 or 59 days compared with a mean (S.D.) value of 29 (10) days in the tetracycline group; P = 0.01]. Within the chloroquine group, FCT and PCT were both shorter in those with cure than in those with R1 resistance, with mean (S.D.) values of 41 (25) and 70 (33) h for FCT (P = 0.09) and 72 (20) and 100 (18) h for PCT (P = 0.01), respectively. Chloroquine does not potentiate the clinical response to quinine against resistant strains of uncomplicated falciparum malaria, nor does it convey any useful antipyretic effect.
Similar articles
-
Comparison of oral artesunate and quinine plus tetracycline in acute uncomplicated falciparum malaria.Bull World Health Organ. 1994;72(2):233-8. Bull World Health Organ. 1994. PMID: 8205643 Free PMC article. Clinical Trial.
-
Quinine-tetracycline for multidrug resistant falciparum malaria.Southeast Asian J Trop Med Public Health. 1996 Mar;27(1):15-8. Southeast Asian J Trop Med Public Health. 1996. PMID: 9031393 Clinical Trial.
-
A randomized comparison of chloroquine, amodiaquine and their combination with pyrimethamine-sulfadoxine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children.Ann Trop Med Parasitol. 2002 Apr;96(3):227-38. doi: 10.1179/000349802125000763. Ann Trop Med Parasitol. 2002. PMID: 12061970 Clinical Trial.
-
Clinical pharmacokinetics of quinine and its relationship with treatment outcomes in children, pregnant women, and elderly patients, with uncomplicated and complicated malaria: a systematic review.Malar J. 2022 Feb 10;21(1):41. doi: 10.1186/s12936-022-04065-1. Malar J. 2022. PMID: 35144612 Free PMC article.
-
A contemporary chemical entities infiltrating in the antimalarial therapy era: a comprehensive review.Folia Med (Plovdiv). 2021 Oct 31;63(5):637-646. doi: 10.3897/folmed.63.e58995. Folia Med (Plovdiv). 2021. PMID: 35851196 Review.
Cited by
-
In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up.Antimicrob Agents Chemother. 2004 Nov;48(11):4271-80. doi: 10.1128/AAC.48.11.4271-4280.2004. Antimicrob Agents Chemother. 2004. PMID: 15504852 Free PMC article.
-
Therapeutic responses to quinine and clindamycin in multidrug-resistant falciparum malaria.Antimicrob Agents Chemother. 2000 Sep;44(9):2395-8. doi: 10.1128/AAC.44.9.2395-2398.2000. Antimicrob Agents Chemother. 2000. PMID: 10952585 Free PMC article. Clinical Trial.